Swiss drugmaker Roche says interest for Covid-19 tests surpasses production Kumar Jeetendra | June 28, 2020 Swiss drugmaker Roche can’t fulfill need for sub-atomic tests to distinguish dynamic COVID-19 diseases, its director revealed to Swiss every day Tagesanzeiger. “The interest surpasses our creation,” Christoph Franz was cited as saying in Saturday’s paper. The choice on where tests were sent to depended, in addition to other things, on contamination rates and the …
Sanofi, GSK to gracefully up to 60 million dosages of COVID-19 antibody to UK Kumar Jeetendra | July 29, 2020 Sanofi And GSK said they had reached a deal with Britain to provide it with as much as 60 million doses of an expected COVID-19 vaccine, and that discussions with different authorities were ongoing. No Vaccine has been prescribed to treat or protect against COVID-19, the respiratory disorder caused by the new coronavirus which has …
US to pay $2.1 billion to Sanofi, GSK in COVID-19 antibody bargain Kumar Jeetendra | July 31, 2020 The US government will pay $2.1 billion to Sanofi SA and GlaxoSmithKline Plc to get COVID-19 vaccines to pay 50 million individuals and to underwrite the drug manufacturers’ testing and manufacturing, the companies said on Friday. The award is the biggest yet from’Operation Warp Speed’, the White House initiative aimed at accelerating access to treatments …
Sterile 96-Well Plate Seal for Cell Culturing by BioChromato Kumar Jeetendra | August 2, 2020 BioChromato, Fujisawa, Japan, has introduced a gamma sterilized version of its Rapid Slit Seal for scientists seeking to eliminate solvent evaporation from samples when culturing cells from 96-well microplates. Rapid Slit Seal is a proprietary self-closing microplate seal which returns to its initial state even when punched having an HPLC or even LC/MS autosampler. This …
Swiss Parenterals Limited received European Union (EU) GMP approval Kumar Jeetendra | August 8, 2020 India’s leading manufacturer of Sterile Injectables company to soon enter the EU markets with various range of injectables and expand gradually. Swiss Parenterals Limited, one of the India’s leading sterile injectable manufacturer has received the European Union (EU) GMP for its two state of the art manufacturing facilities located at Bavla in Gujarat. The certification …
Cipla and Stempeutics collaborate for launch of Stempeucel®, first ‘Made in India’ Cell Therapy to treat Critical Limb Ischemia (CLI) Kumar Jeetendra | August 20, 2020 India, Mumbai, August 20th , 2020: Cipla Limited (BSE: 500087; NSE: CIPLA EQ) referred to as “Cipla” today announced that its partner Stempeutics Research Pvt. Ltd has received regulatory approval by the Drug Controller General of India (DCGI) for the launch of Stempeucel® in India. The product is indicated for the treatment of CLI due …
Granules India arm gets USFDA gesture for ADHD treatment drug Kumar Jeetendra | September 11, 2020 New Delhi, Sep 11 (PTI) Medication firm Granules India Friday said its subsidiary has received marketing approval from the US health regulator for Dexmethylphenidate HCl extended-release capsules, used for the treatment of attention-deficit hyperactivity disorder (ADHD). The approved product is bioequivalent to the reference listed drug Focalin XR of Novartis AG. In a BSE filing, …
India preliminaries for Russia’s ‘Sputnik-V’ antibody may start in next barely any weeks: Dr Reddy’s Kumar Jeetendra | September 22, 2020 Reddy’s Laboratories Ltd could start late-stage Indian clinical trials of Russia’s potential coronavirus vaccine within the next few months, an executive in the Indian drugmaker said on Tuesday. Indian trials of this Sputnik-V vaccine candidate, being developed by Russia’s sovereign wealth fund, will enroll 1,000-2,000 participants and also be conducted at multiple private and government …
Johnson and Johnson’s COVID-19 immunization produces solid invulnerable reaction in early preliminary Kumar Jeetendra | September 26, 2020 Pharmaceutical giant Johnson & Johnson’s experimental COVID-19 vaccine has produced a strong immune response against the novel coronavirus in an early-to-mid stage clinical trial, in accordance with the data published on September 25. “The data demonstrate that a single dose of COVID-19 vaccine, Ad26.COV2.S, induced a powerful neutralising antibody response in nearly all participants aged …
Panthera Biopartners concludes Series A financing with Gresham House Ventures as major investor Kumar Jeetendra | October 2, 2020 Panthera Biopartners (Panthera) has completed a Series A funding round with Gresham House Ventures as a major investor. The capital raised will enable Panthera to further build out its network of clinical trial sites across the UK and overseas and increase its team of clinical trial experts in serving both pharma and patients. Panthera Chairman …
Pfizer changes convention for virus vaccine: study Kumar Jeetendra | October 13, 2020 Drugmaker Pfizer has modified the protocol for its late-stage study of its vaccine against the new coronavirus, this time to include more young participants. The company said on Monday that it’s received permission from the Food and Drug Administration to include adolescents aged 12 through 15 in its global COVID-19 vaccine study. New York-based Pfizer …
Zydus Cadila gets speculative USFDA gesture for generic drug Kumar Jeetendra | October 19, 2020 New Delhi, Oct 19 Drug firm Zydus Cadila on Monday said it has received tentative approval from the US health regulator to advertise Tofacitinib extended-release pills, used to treat ulcerative colitis, in the American market. The company has received tentative approval from the US Food and Drug Administration (USFDA) for the item which is the …
